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Enzymatically regulated demineralisation of pathological bone 
using sodium hexametaphosphate 
Neil Eisenstein,
ab
 Richard Williams,
a
 Sophie Cox,
a
 Sarah Stapley,
b
 and Liam Grover
*a 
The pathological formation of bone in soft tissue can result in significant disability, prevent prosthetic limbs from fitting, 
and limit joint movement. A range of conditions exist, which are characterised by this local tissue ossification. The 
awareness of one such condition, heterotopic ossification, has increased recently due to the extraordinarily high incidence 
of the condition in military amputees (64.6%).  Although the process of formation is biologically mediated through a 
massive inflammatory response, there is currently no adequate treatment or prophylaxis for the condition. This study 
investigates the use of hexametaphosphate (HMP) as a demineralising agent for the treatment of pathological ossification. 
Other demineralising agents exist but their application is limited due to unwanted effects on biological processes such as 
blood clotting and an inability to control their activity. This study demonstrates, for the first time, that the demineralising 
effect of HMP can be modified by local pH and is controlled through the activity of alkaline phosphatase, an enzyme that is 
found throughout the body. HMP was shown, using micro computed tomography, to cause large scale demineralisation of 
samples of pathological bone and was able to inhibit hydroxyapatite precipitation in a supersaturated solution. Stiffness 
and maximum force to failure of rat tibiae incubated in HMP were 49% (p = 0.001) and 41% (p = 0.03) lower, respectively, 
than controls. In contrast, no significant difference was observed in yield force, demonstrating specificity of action of HMP 
against hydroxyapatite, with no unwanted effect on collagen. Contrary to established understanding of the mechanism of 
its dissolution of calcium phosphate salts, micro X-ray fluorescence measurements of the hydroxyapatite surfaces 
suggested that the demineralising effect was mediated in the solution rather than surface binding of HMP.  These findings 
suggest that HMP is effective at dissolving hydroxyapatite and, as such, is a promising a candidate for the treatment of a 
range of pathological ossifications. 
1. Introduction 
Heterotopic ossification (HO) is the pathological formation of 
lamellar bone in soft tissues. It causes disabling symptoms of 
pain, ankylosis, ulceration of the skin, peripheral nerve injury, 
and prosthetic limb fitting problems.
1, 2
 Due to the large 
numbers of combat injured patients from the conflicts in Iraq 
and Afghanistan, the incidence of HO is increasing. Radiological 
evidence of HO is found in 64.6% of combat injured patients.
3
 
In a series of military casualties who required limb amputation, 
the incidence was 79.6% if the amputation was performed 
through the zone of injury.
4
 In the civilian setting, the 
incidence of HO after amputation may be lower, with 22.8% of 
patients reporting symptomatic HO.
2
 The incidence of 
radiological evidence of HO secondary to other causes has 
been reported as follows: traumatic brain injury 37%, spinal 
cord injury 5 to 60%, hip replacement surgery 5%, fractures of 
the distal humerus 8.6%, and burn injuries 0.15%.
5-9
 
Bisphosphonates, non-steroidal anti-inflammatory drugs 
(NSAIDs), and radiotherapy are the main preventative 
therapies currently available. NSAIDS are favoured due to their 
availability and ease of administration but have many side 
effects that may make them unsuitable for traumatically 
injured patients. These include blood clotting dysregulation, 
gastrointestinal ulceration, renal injury, and an increased risk 
of non-union.
10, 11
 Radiotherapy has been used to prevent HO 
but there is significant controversy surrounding the timing and 
dose of treatment.
12
 A Cochrane review of bisphosphonate use 
for HO prophylaxis found no evidence of efficacy. Despite this, 
they are still used widely in clinical practice.
13
 
Non-surgical options for the alleviation of symptoms 
related to HO include rest, analgesia, nerve blocks, and nerve 
ablations.
14
 However, these treatments are only partially 
effective and many patients require surgery to alleviate their 
symptoms. In a series of civilian patients who underwent 
amputation for trauma, 11% required surgical HO excision.
2
 
This figure is 19% in combat-related trauma patients.
4
 Surgery 
caries risks of pain, infection, anaesthetic complications, and 
delay in patient rehabilitation (a mean interval between injury 
and excision of 8.2 months).
4
 Therefore, there is a need to 
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develop new methods for the treatment of this debilitating 
condition. 
Polyphosphates are a family of chemical compounds 
containing chains of phosphorous atoms covalently linked by 
phosphoester bonds. They can be linear or cyclical (Fig. 1) and 
the chain length can vary from one (orthophosphate) to many 
thousands.  
Polyphosphates have been shown to be potent regulators 
of biomineralisation. The addition of minute concentrations 
(10
-7 
M) of HMP to a saturated calcium phosphate solution has 
been shown to inhibit crystallisation.
15, 16 
Further, incubation 
of chick femurs in the presence of polyphosphates can inhibit 
mineralisation.
17
 Detailed mechanistic work to attempt to 
understand the interaction between hydroxyapatite (HA) 
(Ca10(PO4)6(OH)2) and a range of polyphosphates showed that 
HMP could dissolve HA in an inorganic system.
18
 The proposed 
mechanism of dissolution was the substitution of the 
polyphosphate’s terminal phosphate group into the HA crystal 
lattice.   
 In vivo, the activity of condensed phosphates is regulated 
by phosphatase enzymes, such as inorganic pyrophosphatase 
and alkaline phosphatase (ALP), which function to mediate 
hydrolysis of the phosphoester bridges between the 
orthophosphate moieties. ALP, is of particular interest in the 
regulation of condensed phosphates in vivo since it is present 
in five isoforms throughout the body. The ubiquity of this 
family of enzymes means that ALP may enable the regulation 
of HMP following administration, such that its demineralising 
activity can be localised and is unlikely to have any deleterious 
systemic effects.  
Many researchers are currently working on HO prophylaxis 
but all of these approaches focus on the upstream biological 
processes that lead, eventually, to ectopic bone formation. 
Examples include selective agonism of the retinoic acid 
receptor gamma pathway, remote ATP hydrolysis, and 
administration of echinomycin.
19-21
 However, upstream 
inhibition can never treat HO once it has formed. The 
application of the results presented in this paper will be the 
development of a clinically relevant formulation of HMP. This 
would be used to treat patients at high risk of developing HO 
as well as those in which the pathological bone had already 
formed. 
In this study, the demineralising affects of HMP on 
hydroxyapatite monoliths and pathological bone samples were 
determined.  The mechanism of this process was investigated 
using micro X-ray fluorescence (micro-XRF), which allowed us 
to determine whether the process was surface mediated as 
previously reported in the literature.  Finally, the potential for 
the regulation of mineralising activity was evaluated by 
controlling local pH value and through the exposure of HMP to 
ALP. 
 
 
 
 
2. Experimental 
2.1 Materials and Methods 
2.1.1 Hydroxyapatite Pellet Dissolution. Disc-shaped 
pellets of HA were formed by isostatically pressing 400 mg of 
HA powder (Sigma-Aldrich, Gillingham, UK) with 100 μL 
deionised water (diH2O) at 2 kN for 5 seconds. These were 
sintered at 600 
o
C for 1 hour. After cooling in ambient 
conditions, pellets were weighed and incubated at room 
temperature (20 
o
C) in 50 ml of a 0.1 M solution of each of the 
following reagents: sodium pyrophosphate decahydrate 
(Na4P2O7·10H2O), sodium tripolyphosphate (Na5P3O10), 
trisodium trimetaphosphate (Na3P3O9) (all Sigma-Aldrich), and 
sodium HMP (Na6P6O18) (Fisher, Loughborough, UK). 
Ethylenediaminetetraacetic acid (EDTA) (C10H16N2O8) (Sigma-
Aldrich) was used as a positive control. Before incubation, each 
reagent was adjusted to pH 7.4 with 0.1 M NaOH or 0.1 M HCl. 
There were triplicate repeats of each condition. The pH-
adjusted media were replaced every 3.5 days. The pellets were 
removed from solution every 3.5 days, surface fluid removed 
with absorbent paper, and weighed. After 21 days the pellets 
were recovered (except for the EDTA group, which had 
dissolved completely), dried overnight at 80 
o
C, and were then 
analysed by micro XRF. 
2.1.2 Micro X-Ray Fluorescence. Elemental maps of the 
recovered and dried HA pellets were generated using a 
Tornado M4 micro-XRF system (Bruker Nano Gmbh, Berlin, 
Germany) fitted with a Rhodium micro focus X-Ray tube and a 
polycapillary lens. The X-Ray spot size from the polycapillary 
lens was 25 μm. All samples were analysed under ambient 
conditions with an X-Ray tube voltage of 50 kV and a tube 
current of 400 μA. The X-rays were rastered over the sample 
surface with a step size of 100 μm and an XRF spectrum was 
collected at each point with an acquisition time per pixel of 2.5 
ms. Elemental maps were then generated in real time by 
gating around the Phosphorous Kα1 (2.0137 keV) and the 
Calcium Kα1 (3.692 keV) X-Ray fluorescence emission peaks in 
the XRF spectra, creating an image where pixel intensity 
represented detected X-Ray counts per second per eV from 
each measurement point on the sample. Pixel intensity 
increased monotonically with X-Ray counts with maximum 
pixel intensity normalised to the highest count rate per eV for 
a given element across the whole sample. The instrument was 
set to map samples three times to generate a single averaged 
map for each element. 
2.1.3 Hydroxyapatite Sol Dissolution. HA sol was 
synthesised according to the method of Afshar et al.
22
 After 
aging overnight, the sol was added to serial dilutions of HMP in 
a 96-well plate. Each concentration was conducted in 
triplicate. diH2O was added to each well to give a constant final 
well volume of 245 µL. A Glomax 9301-010 plate reading 
spectrophotometer (Promega, Wisconsin, USA) was used to 
measure light transmission through the sample at 650 nm as a 
quantitative determination of the degree of dissolution. 
Results were normalised to a diH2O blank. This experimental 
method was repeated with adjustment of the pH to 6.2, 7.4, 
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and 9.6 using 0.1 M HCl or 0.1 M NaOH as required. See 
supplementary figure 1. for calibration data.  
2.1.4 Alkaline Phosphatase Control Of HMP. 3.6 mL of 
undiluted HA sol was dissolved completely in 25 mL 0.1 M 
HMP (adjusted to pH 7.4 using 0.1 M NaOH). The resulting 
solution was optically clear on macroscopic examination. 2 mL 
aliquots of this stock solution were incubated at 37 
o
C for 9 
days with addition of either 400 units (in 200 µL) of bovine ALP 
(Sigma-Aldrich) for the experimental samples or 200 µL diH2O 
for the control samples. The optical density of the solution was 
measured at day zero and day nine using a plate-reading 
spectrophotometer (see above). Each condition was 
conducted in triplicate and the results compared using a two-
tailed Student’s t-test.  
2.1.5 Rat Tibia Mechanical Testing. Three pairs of tibiae 
were harvested immediately post mortem from male Lister 
hooded rats of 275-325 g bodyweight. Baseline non-
destructive 4-point bend testing was performed on all of the 
samples using a Bose Electroforce 5500 mechanical tester 
(Bose / TA Instruments, Minnesota, USA). Testing parameters 
were as follows: upper points 4.0 mm apart, lower points 10.4 
mm apart, displacement ramp 0.02 mm/s, non-destructive 
displacement limit 0.2 mm, destructive displacement limit 2.0 
mm (see supplementary figure 2). The left-sided tibiae were 
incubated in 50 mL 1% w/v gellan (Gelzan CM, Kelco, Atlanta, 
USA) loaded with 0.1 M HMP. Right-sided tibiae were 
incubated in 50 mL 1% w/v gellan only. The gellan was used as 
an inert delivery vehicle in this experiment. All samples were 
incubated at room temperature (20 
o
C) for 6 days. Destructive 
4-point bending was undertaken after this time. Data from the 
mechanical testing were analysed using WinTest 7 software 
(Bose). Stiffness was calculated as the gradient of the elastic 
region of the force-displacement curves, yield force was 
identified as the force corresponding to the upper limit of the 
elastic region of the force-displacement curves, maximum 
force was taken as the maximum recorded force during 
destructive testing. A two-tailed paired t-test was used to 
compare the stiffness, yield force, and maximum load to 
failure for each pair of tibiae. 
2.1.6 Human HO Sample Dissolution. Samples of human 
HO excised from a single patient who had suffered civilian 
poly-trauma were retrieved from the Human Biomaterials 
Resource Centre at the University of Birmingham. These were 
incubated in 5 mL of either 0.1 M HMP (adjusted to pH 7.4 
with 0.1 M NaOH) or diH2O as a control for 7 days. Before and 
after incubation, these samples were wrapped in parafilm and 
placed inside a polystyrene sample tube. These were scanned 
using a Bruker SkyScan 1172 X-ray micro computed 
tomography (microCT) scanner (Bruker, Coventry, UK) with the 
following settings: no filter, camera position near, pixel size 
4.96 µm, rotation step 0.2
o
, camera resolution 4000 x 2664 
pixels, exposure time 400 ms, frame averaging 6, current 70 
µA, voltage 70 kV. The scans were reconstructed using NRecon 
software (version 1.6.10.2, Bruker microCT) and analysed using 
CTAn (version 1.15.4.0, Bruker microCT). Three-dimensional 
models were generated using a double time cubes algorithm. 
Models were visualised with CTvol (version 2.3.1.0, Bruker 
microCT). The same scanning, reconstruction, and post 
reconstruction processing settings were used for the samples 
before and after incubation. 
2.1.7 Inhibition of HA formation. HA synthesis (as above)
22
 
was undertaken in the presence of 10
-3 
M of each of the 
potential inhibiting reagents: pyrophosphate, linear 
tripolyphosphate, cyclic trimetaphosphate, EDTA, and HMP. 
The reaction products were aged for 1 hour then centrifuged 
(4000 rpm for 10 minutes) and washed with diH2O three times. 
The product was dried overnight at 80 
o
C and finely ground. X-
ray diffraction patterns were generated using a Bruker D8 
diffractometer (2θ 5-80
o
) and analysed using Bruker EVA 
diffrac.suite software (version 3.1). The raw diffraction data 
was baseline corrected but not smoothed. Reference data for 
HA (PDF 00-009-0432) and calcium hydroxide (Ca(OH)2) (PDF 
00-044-1481) were obtained using the software program PDF-
4+ with database version 4.4103 (International Centre for 
Diffraction Data). 
3. Results and Discussion  
3.1 HMP Dissolves HA in vitro and ex vivo  
Incubation in HMP reduced the mean mass of HA pellets by 
30.2% over 504 hours (Fig. 2). The EDTA positive control 
reduced the mass of pellets by 95.0% in the same time period. 
diH2O water control, cyclical trimetaphosphate, linear 
tripolyphosphate, and pyrophosphate had negligible effect on 
HA pellet mass. 
Incubation of rat tibiae in gellan loaded with HMP caused a 
reduction in stiffness and maximum load to failure. Stiffness 
was 49% lower in the HMP/gellan group compared to gellan-
only controls (p = 0.001). Maximum load to failure was 41% 
lower in the HMP/gellan group compared to gellan-only 
controls (p = 0.03) (Fig. 3). There was no significant difference 
in the yield force between the two conditions.  The reduction 
in stiffness of the bone is consistent with the dissolution of 
hydroxyapatite from the bone matrix.
23, 24
 Interestingly, the 
yield force was unaffected by incubation in HMP. As the yield 
force is determined by the collagenous component of bone, 
this finding suggests that HMP is able to dissolve HA from 
within the bone composite structure without affecting the 
collagen component.
25, 26
 
By using the same scanning, reconstruction, and processing 
protocols for the samples before and after incubation, micro-
CT imaging and volume analysis demonstrated that HMP 
caused the demineralisation of samples of human HO at 
physiological pH. The bone volume of the HO sample 
incubated in 0.1 M HMP at pH 7.4 for 7 days decreased from 
11.6 mm
3
 to 3.43 mm
3
, a reduction of 70.4%. The bone volume 
of the control sample changed from 9.34 mm
3
 to 8.76 mm
3
, a 
reduction of 6.2%. Three-dimensional models of the 
mineralised component of the HO samples are shown in Fig. 4. 
The sample incubated in HMP appears grossly attenuated. In 
contrast, the sample incubated in diH2O appears largely 
unchanged compared with its pre-incubation state. 
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3.2 Evidence for Solution-Mediation Dissolution  
Elemental maps illustrate the resulting changes in surface 
chemistry as a result of incubation in the polyphosphates for 
21 days (Fig. 5). diH2O, HMP, linear tripolyphosphate, and 
cyclical trimetaphosphate all showed little change in Ca:P ratio 
over the period of the study. The pellets incubated in 
pyrophosphate, however, showed an increased phosphorus 
signal distributed heterogeneously across the surface of the 
pellet, suggest the adsorption of pyrophosphate ions to the 
surface of the samples. There are no images for the pellets 
incubated in EDTA as these were dissolved completely.  
The finding that the HMP group did not cause any change 
in the Ca:P ratio compared with deionised water controls is 
significant because, if the mechanism of dissolution was initial 
incorporation of the terminal phosphate group of HMP into 
the HA matrix, an increase in phosphorus signal relative to 
calcium signal would be expected.
18
 The lack of change in Ca:P, 
coupled with the monotonic rate of dissolution was more 
consistent with a solution- rather than surface-mediated 
mechanism. Certainly, HMP has a very strong affinity for Ca
2++ 
ions, forming a 1:1 complex with a high thermodynamic 
stability constant.
27
 Thus it is possible that HMP is complexing 
any available Ca
2++
 ions from the hydroxyapatite matrix and 
forming a highly-stable Ca-HMP complex in solution. Indeed, 
HMP has such a high affinity for cations that it has been 
demonstrated to dissolve kaolin and kaolinite by complexing 
the aluminium cations in these minerals.
28
 
The finding that incubation of HA pellets in pyrophosphate 
caused an increase in the surface phosphorus signal on micro-
XRF suggests adsorption to the surface of the pellet, which is 
consistent with previous reports in the literature.
29
 
 
3.3 HMP Activity is Regulated by pH and Alkaline Phosphatase  
At every concentration of HMP, higher pH values reduced the 
amount of HA sol dissolved (Fig. 6). For a HMP concentration 
of 0.1125 M, the available HA in sol form in the samples at pH 
6.2, 7.4, and 9.6 was 0.15, 13.3, and 23.4 g/L, respectively 
(note: control samples of sol had 26.43 g of HA per L). See 
supplementary figure 3 for additional data derived using HA 
residual mass to demonstrate the HA-dissolving ability of HMP. 
This pH-controlled effect was demonstrated across a range of 
concentrations of HMP spanning four orders of magnitude. 
This may prove to be a key mechanism by which the activity of 
HMP can be targeted towards the sites of pathological bone 
formation in HO. This is because hypoxia is thought to be a key 
step in the biological pathway for HO formation, and hypoxia 
leads to local low pH in tissues through switching toward 
anaerobic respiration and the generation of lactate.
30, 31
 
Therefore, in sites where pH is low and HO is most likely to 
develop, HMP will also be most potent at dissolving HA. While 
these data provide compelling evidence that pH controls the 
HA-dissolving ability of HMP, they do not provide any 
mechanistic explanation for the relationship.  
Addition of ALP to a solution of HA sol dissolved in HMP 
caused HA to precipitate out of solution as demonstrated by a 
change from clear to turbid over 9 days. The mean HA 
concentration in the ALP group increased from 1.08 to 11.8 g/L 
(p = 0.00) whereas that of the control group fell from 1.13 to 
0.94 g/L (p = 0.007) (Fig. 7). See supplementary figure 4 for 
additional data derived using HA residual mass to demonstrate 
the effect of ALP on HA sol concentration.  
ALP is an exophosphatase found in many tissues that can 
cleave the terminal phosphate group from polyphosphates. As 
demonstrated in Fig. 2, shorter chain length polyphosphates 
have little or no HA-dissolving ability. Therefore, we interpret 
the increased turbidity in the presence of ALP to be due to HA 
precipitating out of solution as the solvent (HMP) is cleaved. 
The importance of this is that it demonstrates that ALP-
mediated degradation is a feasible mechanism for the 
inactivation of HMP over time in the body. It would not be 
desirable to deliver a therapeutic agent with HA-dissolving 
activity into the body without the possibility of limiting its 
duration of action. It is noted that, in contrast to the ALP 
group, the HA concentration of the control group decreased. 
This may represent further dissolution of any undissolved HA 
sol over the incubation period. 
 
3.4 HMP Inhibits HA Synthesis 
All of the experiments and results discussed above relate, in 
various ways, to the dissolution of HA by HMP.  In addition to 
dissolving HA, HMP is also able to inhibit its synthesis. 
Polyphosphates (10
-3 
M) were added to the reaction mixture 
when synthesising HA using the Afshar method.
22
 X-ray 
diffraction (XRD) patterns generated from unsintered reaction 
products are shown in Fig. 8. The patterns generated in the 
control sample and in the presence of cyclic trimetaphosphate, 
EDTA, linear tripolyphosphate, and pyrophosphate match the 
reference standard of HA with no detectable secondary 
phases. In contrast, the pattern generated by the sample 
synthesised in the presence of HMP has additional peaks that 
match the reference standard for Ca(OH)2, one of the reaction 
precursors. This suggested that the HMP inhibited the 
formation of HA as previously reported elsewhere.
17, 18, 32
 
Given that HMP was able to reduce the reaction yield of HA 
precipitated in a super-saturated solution, it is possible that in 
vivo, it could inhibit the formation of HA in ectopic bone.
33
  
 
3.5 Application and Future Developments 
The next stage in the development of HMP as a therapeutic 
agent will be to test it upon an in vivo model of heterotopic 
ossification. Selection of the most appropriate model for 
testing will be crucial for allowing researchers to apply any 
findings to clinical development.
34, 35
 
4. Conclusions 
This paper demonstrates that HMP can dissolve 
hydroxyapatite in inorganic and biological settings, that this 
effect is controllable through alteration in pH and through the 
action of ALP, that ex vivo human HO is attenuated by its 
action, and that HA formation can be inhibited in the presence 
of small concentrations of this simple polyphosphate. Existing 
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clinical prophylaxis and current innovations in this field focus 
on the upstream biological pathways. However, chemical 
means of dissolving the final product, hydroxyapatite, could be 
an effective way of addressing this problem and the data 
presented here show this to be a possibility. If efficacy is 
proven in the condition of heterotopic ossification, this opens 
the possibility of broadening the application to other diseases 
of extra-skeletal mineral deposition. 
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Fig. 1 Schematic chemical structures of ionic phosphate and polyphosphates: orthophosphate (Pi), 
pyrophosphate (PPi), linear tripolyphosphate (LTPP), cyclic trimetaphosphate (CTMP), and 
hexametaphosphate (HMP).  
42x22mm (600 x 600 DPI)  
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Fig. 2 Mass loss of hydroxyapatite pellets over time incubated in various potential dissolving agents. This 
demonstrates the potent dissolving ability of hexametaphosphate. Ethylenediaminetetraacetic acid (EDTA) 
was used as a positive control. Deionised water (diH2O), cyclic trimetaphosphate (CTMP), linear 
tripolyphosphate (LTPP), pyrophosphate (PPi), hexametaphospate (HMP). Error bars are +/- SEM.  
82x82mm (300 x 300 DPI)  
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Fig. 3 Results of 4-point mechanical testing of rat tibiae after incubation in either 1% gellan alone or 1% 
gellan loaded with 0.1 M HMP for 6 days. Incubation in HMP caused a significant reduction in the stiffness 
and maximum load to failure compared to matched controls group. Error bars are +/- SEM. * = p<0.05.  
82x82mm (300 x 300 DPI)  
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Fig. 4 Three-dimensional surface-rendered models of the mineralised volumes of samples of heterotopic 
ossification. Before (A) and after (B) incubation in 0.1 M HMP at pH 7.4 for 7 days. Before (C) and after (D) 
incubation in diH2O at pH 7.4 for 7 days. The sample incubated in HMP is clearly attenuated after incubation 
whereas the control sample shows little change. Scale bar = 1 mm.  
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Fig. 5 Micro X-ray fluorescence mapping of calcium and phosphorus on the surface of pellets of 
hydroxyapatite after 21 days of incubation in the following potential dissolving agents: deionised water 
(diH2O), cyclic trimetaphosphate (CTMP), linear tripolyphosphate (LTPP), pyrophosphate (PPi), 
hexametaphosphate (HMP). Note that for each dissolving agent, this figure shows the micro-XRF data for 
different elements on the surface of a single pellet. There were, in fact, triplicate repeats under each 
condition and the changes shown here were typical for all repeats.  
82x102mm (300 x 300 DPI)  
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Fig. 6 Demonstration of the effect of varying the pH and concentration of HMP on the amount of available HA 
in sol form. Lower amounts (in g / L) of available HA sol indicates higher amounts dissolved by the HMP. 
Dissolving ability is increased with increasing concentration and decreasing pH. Error bars are +/- SEM.  
82x82mm (300 x 300 DPI)  
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Fig. 7 Change amount (in g / L) of available HA in sol form in a nearly-saturated solution of HA dissolved in 
0.1 M hexametaphosphate after incubation with either alkaline phosphatase (ALP) or control (diH2O) for 9 
days. Error bars are +/- SEM. * = p<0.05.  
82x82mm (300 x 300 DPI)  
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Fig. 8 X-ray diffraction patterns of the products of hydroxyapatite synthesis. In the presence of 
hexametaphosphate, there is an increased amount of unreacted calcium hydroxide (Ca(OH)2) precursor in 
the product suggesting inhibition of hydroxyapatite crystallisation. The other reagents had no measurable 
effect compared to control. Pyrophosphate (PPi), linear tripolyphosphate (LTPP), ethylenediaminetetraacetic 
acid (EDTA), cyclic trimetaphosphate (CTMP), hexametaphosphate (HMP).  
82x40mm (300 x 300 DPI)  
 
 
Page 14 of 15Journal of Materials Chemistry B
Jo
ur
na
lo
fM
at
er
ia
ls
C
he
m
is
tr
y
B
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
26
 A
pr
il 
20
16
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f B
irm
in
gh
am
 o
n 
26
/0
4/
20
16
 1
4:
00
:4
5.
 
View Article Online
DOI: 10.1039/C6TB00461J
Human heterotopic ossification before (A) and after (B) incubation in hexametaphosphate
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